Interactions of levetiracetam with ethosuximide in the mouse 6 Hz psychomotor seizure model - a type II isobolographic analysis

• Autorzy: Luszczki J. J. , Wlaz A. , Kondrat-Wrobel M. W. , Pyrka D. , Florek-Luszczki M.
• Języki publikacji: EN

Abstrakty

EN

The aim of the present study was to characterize the anticonvulsant effects of levetiracetam in combination with ethosuximide in the mouse 6 Hz psychomotor seizure model. Limbic (psychomotor) seizure activity was evoked in albino Swiss mice by a current (32 mA, 6 Hz, 3 s stimulus duration) delivered via ocular electrodes; type II isobolographic analysis was used to characterize the consequent anticonvulsant interactions between the drug combinations for fixed-ratios of 1:1, 1:2, 1:5 and 1:10. With type II isobolographic analysis, the combinations of levetiracetam with ethosuximide for the fixed-ratios of 1:5 and 1:10 were supra-additive (synergistic; P<0.05 and P<0.01, respectively) in terms of seizure suppression, while the combinations for the fixed-ratios of 1:1 and 1:2 were additive in the mouse 6 Hz psychomotor seizure model. The combinations of levetiracetam with ethosuximide for the fixed-ratios of 1:5 and 1:10 appear to be particularly favorable combinations exerting supra-additive interaction in the mouse 6 Hz psychomotor seizure model. Finally, it may be concluded that because of the synergistic interactions between levetiracetam and ethosuximide, the combination might be useful in clinical practice.

Słowa kluczowe

EN

6 Hz psychomotor seizure model; antiepileptic drug; drug interaction; ethosuximide; levetiracetam; isobolographic analysis

• Wydawca: -
• Czasopismo: Journal of Pre-Clinical and Clinical Research
• Rocznik: 2014
• Tom: 08
• Numer: 2
• Opis fizyczny: p.76-80,fig.,ref.

Twórcy

autor

Luszczki J. J.

• Isobolographic Analysis Laboratory, Institute of Rural Health, Lublin, Poland
• Department of Pathophysiology, Medical University, Ceramiczna 1, 20-150 Lublin, Poland

autor

Wlaz A.

• Department of Pathophysiology, Medical University, Ceramiczna 1, 20-150 Lublin, Poland

autor

Kondrat-Wrobel M. W.

• Department of Pathophysiology, Medical University, Ceramiczna 1, 20-150 Lublin, Poland

autor

Pyrka D.

• Department of Pathophysiology, Medical University, Ceramiczna 1, 20-150 Lublin, Poland

autor

Florek-Luszczki M.

• Department of Public Health, Institute of Rural Health, Lublin, Poland

Bibliografia

• 1. Kwan P, Brodie MJ. Combination therapy in epilepsy: when and what to use. Drugs 2006; 66: 1817.
• 2. Deckers CLP, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 2000; 41: 1364.
• 3. Perucca E. Pharmacological principles as a basis for polytherapy. Acta Neurol Scand. 1995; Suppl.162: 31.
• 4. Stephen LJ, Brodie MJ. Seizure freedom with more than one antiepileptic drug. Seizure 2002; 11: 349.
• 5. Łuszczki JJ, Czuczwar SJ. Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis.Epilepsia 2004; 45: 895.
• 6. EP 2 462 990 A1. European Patent Application https://data.epo.org/ publication-server/rest/v1.0/publication-dates/20120613/patents/EP2462990NWA1/document.pdf (access: 2014.01.13).
• 7. Wojda E, et al. Isobolographic characterization of interactions of levetiracetam with the various antiepileptic drugs in the mouse 6 Hzpsychomotor seizure model. Epilepsy Res. 2009; 86: 163.
• 8. Florek-Łuszczki M, Wlaź A, Łuszczki JJ. Interactions of levetiracetam with carbamazepine, phenytoin, topiramate and vigabatrin in the mouse6Hz psychomotor seizure model – A type II isobolographic analysis.Eur J Pharmacol. 2014; 723: 410.
• 9. Łuszczki JJ, et al. Additive interaction of levetiracetam with lamotrigine in the mouse 6 Hz psychomotor seizure model – an isobolographic analysis. Curr Issues Pharm Med Sci. 2013; 26: 82.
• 10. Łuszczki JJ, et al. Isobolographic characterization of interaction of levetiracetam with clobazam in the mouse 6 Hz psychomotor seizuremodel. J Pre-Clin Clin Res. 2012; 6: 25.
• 11. Barton ME, et al. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res. 2001;47: 217.
• 12. Dudra-Jastrzebska M, et al. Isobolographic characterization of the anticonvulsant interaction profiles of levetiracetam in combination withclonazepam, ethosuximide, phenobarbital and valproate in the mousepentylenetetrazole-induced seizure model. Seizure 2009; 18: 607–614.
• 13. Litchfield JT, Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther. 1949; 96: 99–113.
• 14. Tallarida RJ. Drug synergism and dose-effect data analysis. Chapman & Hall/CRC, Boca Raton, 2000.
• 15. Porreca F, Jiang Q, Tallarida RJ. Modulation of morphine antinociception by peripheral [Leu5]enkephalin: a synergistic interaction. Eur J Pharmacol. 1990; 179: 463–468.
• 16. Łuszczki JJ, et al. Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximalelectroshock-induced seizure model. Naunyn-Schmiedebergs ArchPharmacol. 2006; 373: 169–181.
• 17. Gąsior M, et al. Influence of nicardipine, nimodipine and flunarizine on the anticonvulsant efficacy of antiepileptics against pentylenetetrazol in mice. J Neural Transm. 1996; 103: 819–831.
• 18. Madeja M, et al. Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action? Neuropharmacology 2003; 45: 661–671.
• 19. Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002; 43: 9–18.
• 20. Niespodziany I, Klitgaard H, Margineanu DG. Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices. Neurosci Lett. 2001; 306: 5–8.
• 21. Rigo JM, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol. 2002; 136: 659–652.
• 22. Palma E, et al. GABA(A)-current rundown of temporal lobe epilepsy is associated with repetitive activation of GABA(A) “phasic” receptors. Proc Natl Acad Sci USA. 2007; 104: 20944.
• 23. Lynch BA, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA. 2004; 101: 9861–9866.
• 24. Brodie MJ, Schachter SC. Fast Facts. Epilepsy. 2nd ed. Oxford, Health Press, 2001.
• 25. Crunelli V, Leresche N. Block of thalamic T-type Ca(2+) channels by ethosuximide is not the whole story. Epilepsy Curr. 2002; 2: 53–56.

Identyfikatory

DOI

10.5604/18982395.1135654